XML 26 R15.htm IDEA: XBRL DOCUMENT
v3.21.1

Stockholders' Equity | 9 Months Ended
--- | ---
Sep. 30, 2020
Stockholders' Equity Note [Abstract] |
Stockholders' Equity | Note 9. Stockholders’ Equity Common Stock Authorized Shares The Company has 45,000,000 common shares authorized with a par value of $0.001 per share. Issuance of Shares Pursuant to Conversion of Series A Preferred Stock During January 2020, the Company issued 5,264 shares of common stock to a holder of its Series A Convertible Preferred Stock upon the conversion of 2,000 of such shares of Series A Convertible Preferred Stock. During February 2020, the Company issued an aggregate of 172,369 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 65,500 of such shares of Series A Convertible Preferred Stock. During April 2020, the Company issued an aggregate of 1,043,935 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 396,695 of such shares of Series A Convertible Preferred Stock. During May 2020, the Company issued an aggregate of 51,316 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 19,500 of such shares of Series A Convertible Preferred Stock. During August 2020, the Company issued 13,158 shares of common stock to a holder of its Series A Convertible Preferred Stock upon the conversion of 5,000 of such shares of Series A Convertible Preferred Stock. Issuance of Shares to Current and Former Employees and Directors On January 8, 2020, the Company issued 50,000 shares of common stock to a former employee per the terms of a settlement agreement. On March 12, 2020, the Company issued 16,667 shares of common stock to an employee pursuant to a vesting schedule. On April 15, 2020, the Company issued 3,913 shares of common stock to an employee pursuant to a vesting schedule. On April 16, 2020, the Company issued 5,264 shares of common stock valued at $36,584.80 or $6.95 per share to a director pursuant to a vesting schedule. On April 21, 2020, the Company issued 30,303 shares of common stock to a former employee pursuant to a vesting schedule. On June 24, 2020, the Company issued 25,000 shares of common stock to an employee pursuant to a vesting schedule. On August 25, 2020, the Company issued 87,255 shares of common stock valued at $142,226 to a former employee per the terms of a settlement agreement, settling $125,000 of accrued expenses and recorded a loss on settlement of $17,226. Issuance of Shares Pursuant to Exercises of Common Stock Warrants On April 14, 2020, a holder of common stock warrants exercised 7,000 warrants for a cash payment of, $38,570. Issuance of Shares Pursuant to Cashless Exercises of Common Stock Warrants During April 2020, holders of common stock warrants exercised an aggregate of 520,925 warrants using a cashless exercise into 321,155 shares of common stock. During May 2020, holders of common stock warrants exercised an aggregate of 56,982 warrants using a cashless exercise into 26,034 shares of common stock. During August 2020, holders of common stock warrants exercised an aggregate of 116,448 warrants using a cashless exercise into 68,715 shares of common stock. Issuance of Shares Pursuant to Cashless Exercises of Stock Options During April 2020, holders of common stock options exercised an aggregate of 105,028 options using a cashless exercise into 57,534 shares of common stock. During August 2020, holders of common stock options exercised an aggregate of 55,263 options using a cashless exercise into 28,890 shares of common stock. Issuance of Shares Pursuant to Settlement of Accounts Payable On April 16, 2020, the Company issued 100,000 shares of common stock in full settlement of $640,517 of accounts payable. The shares had a fair value of $6.95 per shares. On May 12, 2020, the Company issued 104,567 shares of common stock in full settlement of $93,150 of accounts payable. The shares had a fair value of $5.76 per shares. On June 24, 2020, the Company issued 80,000 shares of common stock and warrants to purchase 100,000 shares of common stock, of which 50,000 shall be exercisable at $3.80 per share and the remaining 50,000 shall be exercisable at $5.80 per share, in each case for a term of 5 years, in connection with the termination of a consulting arrangement and in full settlement of any and all claims again the Company. The Company had previously accrued $195,000 in connection with this consulting arrangement. The stock had a fair value of $5.76 per share. On August 27, 2020, the Company issued 17,000 shares of common stock valued at $40,800 in full settlement of $48,790 of accounts payable. The shares had a fair value of $2.20 per shares. The Company recorded a loss on settlement of accounts payable of $7,990. On September 10, 2020, the Company issued 140,000 shares of common stock valued at $806,400 in full settlement of $88,950 of accounts payable and recorded a loss on settlement of $547,756. The shares had a fair value of $5.76 per share. Equity Financing During May 2020, the Company received $515,000 of a committed $565,000 from the sale of 135,527 shares of common stock (at a price of $3.80 per share) and warrants to purchase 169,409 shares of common stock, at an exercise price of $4.00 per share. As of September 30, 2020, the full amount has not been received and the shares and warrants have not been issued. The $515,000 received through September 30, 2020 is included in equity financing within current liabilities on the unaudited condensed consolidated balance sheet. Stock Incentive Plan The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the nine months ended September 30, 2020 were:
|  | Warrant Grants |  |  | Stock Option Grants |  |  | Restricted Stock Units |
|  | Number of shares subject to warrants |  |  | Weighted- average exercise price per share |  |  | Number of shares subject to options |  |  | Weighted- average exercise price per share |  |  | Number of shares subject to restricted stock units |  |  | Weighted- average exercise price per share |
Balance at December 31, 2019 |  |  | 1,311,916 |  |  | $ | 9.35 |  |  |  | 338,595 |  |  | $ | 5.26 |  |  |  | 630,303 |  |  | $ | - |
Granted |  |  | 100,000 |  |  |  | 4.75 |  |  |  | - |  |  |  | - |  |  |  | 2,222,984 |  |  |  | - |
Exercised |  |  | (681,619 | ) |  |  | 5.57 |  |  |  | (160,291 | ) |  |  | 4.78 |  |  |  | (46,931 | ) |  |  | - |
Cancelled/Forfeited |  |  | (88,027 | ) |  |  | 31.24 |  |  |  | (5,263 | ) |  |  | 24.70 |  |  |  | (475,000 | ) |  |  | - |
Balance at September 30, 2020 |  |  | 642,270 |  |  | $ | 9.71 |  |  |  | 173,041 |  |  | $ | 5.12 |  |  |  | 2,331,356 |  |  | $ | - |
Exercisable at September 30, 2020 |  |  | 642,270 |  |  | $ | 9.71 |  |  |  | 173,041 |  |  | $ | 5.12 |  |  |  | 642,311 |  |  | $ | - |
The Company has classified the warrant as having Level 2 inputs, and has used the Black-Scholes option-pricing model to value the warrant. The fair value at the issuance dates for the above warrant was based upon the following management assumptions:
|  | Issuance dates |
Risk-free interest rate |  |  | 1.00 | %
Expected dividend yield |  |  | 0 | %
Expected volatility |  |  | 100 | %
Term |  |  | 5 years |
Fair value of common stock |  | $ | 2.37 |
The Company’s outstanding warrants and options at September 30, 2020 are as follows:
Warrants Outstanding |  | Warrants Exercisable
Exercise Price Range |  | Number Outstanding |  |  | Weighted Average Remaining Contractual Life (in years) |  |  | Weighted Average Exercise Price |  |  | Number Exercisable |  | Weighted Average Exercise Price |  |  | Intrinsic Value |
$3.80 - $141.17 |  |  | 642,270 |  |  |  | 3.03 |  |  | $ | 9.71 |  |  | 642,270 |  | $ | 9.71 |  |  |  | - |
Options Outstanding |  | Options Exercisable
Exercise Price Range |  | Number Outstanding |  |  | Weighted Average Remaining Contractual Life (in years) |  |  | Weighted Average Exercise Price |  |  | Number Exercisable |  | Weighted Average Exercise Price |  |  | Intrinsic Value |
$2.64 - $28.50 |  |  | 173,041 |  |  |  | 3.61 |  |  | $ | 5.12 |  |  | 173,041 |  | $ | 5.12 |  |  |  | - |
As of September 30, 2020 and December 31, 2019, the total unrecognized expense for unvested stock options and restricted stock awards was $3,311,888 and $3,236,292, respectively, to be recognized over a one to three year period for restricted stock awards and one year for option grants from the date of grant. Stock-based compensation expense for the three and nine months ended September 30, 2020 and 2019 was as follows:
|  | For the three months ended |  |  | For the nine months ended |
|  | September 30, |  |  | September 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Stock-based compensation expense |  | $ | 488,304 |  |  | $ | 433,438 |  |  | $ | 2,844,851 |  |  | $ | 6,283,811 |
Stock-based compensation expense categorized by the equity components for the three and nine months ended September 30, 2020 and 2019 was as follows:
|  | For the three months ended |  |  | For the nine months ended |
|  | September 30, |  |  | September 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Common stock |  | $ | 488,307 |  |  | $ | 359,910 |  |  | $ | 2,844,851 |  |  | $ | 764,807 |
Stock option awards |  |  | - |  |  |  | 73,528 |  |  |  | - |  |  |  | 196,074 |
Transfer of common stock by founders to contractors |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 5,322,930 |
Total |  | $ | 488,307 |  |  | $ | 433,438 |  |  | $ | 2,844,851 |  |  | $ | 6,283,811 |

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration